GlaxoSmithKline plc (GSK) Price Target Increased to GBX 1,750 by Analysts at J P Morgan Chase & Co

GlaxoSmithKline plc (LON:GSK) had its price objective upped by investment analysts at J P Morgan Chase & Co from GBX 1,670 ($21.13) to GBX 1,750 ($22.14) in a note issued to investors on Friday, May 12th. The firm currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s price target would indicate a potential upside of 3.86% from the company’s current price.

GSK has been the topic of a number of other research reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a GBX 1,700 ($21.51) price objective on shares of GlaxoSmithKline plc in a research note on Monday, February 6th. Liberum Capital reiterated a “buy” rating and issued a GBX 1,900 ($24.04) target price on shares of GlaxoSmithKline plc in a report on Thursday, March 9th. Goldman Sachs Group, Inc. (The) lifted their target price on GlaxoSmithKline plc from GBX 1,800 ($22.77) to GBX 1,850 ($23.40) and gave the stock a “buy” rating in a report on Tuesday, January 24th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Thursday, January 26th. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a GBX 1,750 ($22.14) target price on shares of GlaxoSmithKline plc in a report on Thursday, February 9th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of GBX 1,745.17 ($22.08).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Shares of GlaxoSmithKline plc (GSK) traded up 0.06% during mid-day trading on Friday, reaching GBX 1685.00. The company’s stock had a trading volume of 19,969,256 shares. The company’s 50-day moving average price is GBX 1,647.07 and its 200-day moving average price is GBX 1,604.10. The stock’s market capitalization is GBX 82.33 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,363.00 and a 12-month high of GBX 1,745.56.

The company also recently announced a dividend, which will be paid on Thursday, July 13th. Shareholders of record on Thursday, May 11th will be given a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.21%. The ex-dividend date of this dividend is Thursday, May 11th.

COPYRIGHT VIOLATION WARNING: This story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.com-unik.info/2017/06/17/jpmorgan-chase-co-increases-glaxosmithkline-plc-gsk-price-target-to-gbx-1750-updated-updated-updated.html.

In related news, insider Dominic Redfern purchased 230 shares of GlaxoSmithKline plc stock in a transaction dated Thursday, April 13th. The stock was purchased at an average cost of GBX 1,639 ($20.73) per share, with a total value of £3,769.70 ($4,768.75). Also, insider Vivienne Cox purchased 335 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, April 26th. The stock was bought at an average cost of GBX 1,583 ($20.03) per share, with a total value of £5,303.05 ($6,708.48). Over the last ninety days, insiders have acquired 662 shares of company stock valued at $1,067,188.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit